The TEL and AML1 genes are common targets of chromosomal translocations in hematopoietic malignancies. The TEL-AML1 fusion gene, created by the t(12;21), is the most common genetic alteration in childhood acute lymphoblastic leukemia and is associated with a favorable outcome. This review summarizes the roles of the TEL and AML1 proteins in hematopoiesis, the potential transforming mechanisms of TEL fusion proteins, and the clinical significance of the TEL-AML1 fusion.
Introduction
The cloning of genes altered by leukemia-associated chromosomal rearrangements has provided critical insights into the pathogenic mechanisms responsible for the transformation of hematopoietic cells. 1 In addition, this work has resulted in the ability to classify leukemias into clinically relevant subgroups based on their underlying molecular genetic lesions. To date, these efforts have had their most significant impact on the medical management of pediatric patients with acute lymphoblastic leukemia (ALL). 2 Several molecular genetic abnormalities, including the E2A-PBX1, BCR-ABL and MLL-AF4 fusion genes, are presently used as risk-stratifying features to determine appropriate therapy for pediatric ALL patients. A recently identified genetic lesion that has been proposed as an addition to this list is the t(12;21)(p13;q22), which encodes a chimeric TEL-AML1 protein. In this review, we will summarize our present understanding of the molecular biology of this chromosomal translocation and its encoded product. We will then review the data on the clinical significance of this abnormality and the proposed role of its detection in therapeutic decisions.
TEL and AML1, the targets of the t(12;21)
The genes altered by the t(12;21), TEL and AML1, are the two most common targets of chromosomal rearrangements in human leukemias, and are fused to a wide range of partner genes in both myeloid and lymphoid leukemias. 3, 4 The TEL gene (named for translocation, ets, leukemia, and also known as ETS-Variant Gene 6 or ETV6) is a member of the Ets family of transcription factors that is characterized by a C-terminal winged helix-turn-helix DNA-binding domain referred to as the ETS domain. [5] [6] [7] Like other members of this family, TEL functions as a sequence-specific DNA-binding transcriptional regulator. 5 Although DNA binding is mediated through the ETS domain, it is likely influenced by protein-protein inter-actions mediated through other portions of the molecule. TEL also contains an N-terminal helix-loop-helix (HLH) domain, called the pointed domain, that is found in only a subset of Ets family members ( Figure 1) . 7, 8 The HLH domain of TEL mediates homotypic oligomerization and appears to be critical for normal function. [8] [9] [10] [11] Although TEL abnormalities generally occur in hematopoietic malignancies, TEL is normally widely expressed in both hematopoietic and non-hematopoietic tissues. 6, 12 Moreover, results from TEL-deficient mice suggest that during development, TEL is not required for the establishment of hematopoiesis. 12 Instead, TEL-deficient mice suffer from profound developmental defects and die during early embryogenesis from defective yolk sac angiogenesis and excessive mesenchymal and neuronal cell death. These results suggest that normal TEL function is required for the maintenance of the developing yolk sac vascular network and for the survival of selected cell populations. Its role in angiogenesis is interesting in light of the recent identification of common hemangioblasts. Recently, Wang et al 13 investigated the role of TEL in post embryologic hematopoiesis by generating chimeric mice with TEL-deficient ES cells. They demonstrated that although TEL is not required for fetal liver hematopoiesis, it is essential for the establishment of bone marrow hematopoiesis of all lineages. Therefore, in contrast to other transcription factors, such as AML1 (see below), that are required for yolk sac or liver hematopoiesis, TEL is the first transcriptional protein specifically needed for hematopoiesis within the bone marrow.
AML1, also known as CBFA2, the other target of the t(12;21), was initially cloned as the chromosome 21 target of the t(8;21) and encodes a transcription factor that binds the enhancer core sequence, TGT/cGGT.
14-16 AML1's DNAbinding affinity is increased through heterodimerization with the CBF␤ protein, and both its DNA-binding and interaction with CBF␤ are mediated through a central 118 amino acid domain that is highly homologous to the Drosophila runt domain. 17, 18 A high level of expression of AML1 is limited to cells of the hematopoietic lineage and to ganglion cells of the developing nervous system. The enhancer core motif to which AML1/CBF␤ binds has been shown to be critical for the tissue-specific expression of several hematopoietic-specific genes, including those that encode myeloperoxidase, the receptor for CSF-1, the subunits of the T cell antigen receptor, neutrophil elastase, and the cytokines IL-3 and GM-CSF. Although the core enhancer sequence is important for the hematopoietic-specific expression of these genes, expression is also dependent on the presence of adjacent binding sites for lineage-restricted transcription factors including myb, CEBP␣, and interestingly, Ets family members. This observation suggests that AML1/CBF␤ functions a transcriptional organizer that recruits tissue-specific factors to form a nucleoprotein complex, or enhanceosome, that stimulates lineage-restricted transcription.
Consistent with a critical role in normal hematopoiesis, gene targeting experiments have demonstrated that both AML1 and CBF␤ are essential for the formation of the definitive hematopoietic system. [19] [20] [21] [22] Null mutation in either gene results in an embryonic lethal phenotype with death during mid-embryonic development from a complete absence of fetal liver-derived hematopoiesis and lethal central nervous system (CNS) hemorrhages. Although primitive yolk sac-derived erythropoiesis appears normal, no definitive hematopoietic progenitors of any lineage are present. The mice are thus characterized by an evolving anemia and a complete absence of circulating platelets. Whether the lethal CNS bleeds result from this hematopoietic defect or from the absence of critical AML1 functions in the affected CNS tissues remains to be defined. The hematopoietic defect that results from the loss of AML1 is intrinsic to the definitive hematopoietic stem cell and is not the result of a defect in the fetal liver microenvironment. These findings suggest that AML1/CBF␤ functions as a master regulatory switch that establishes, by both positive and negative regulation, a transcriptional cascade involved in critical cell fate decisions necessary for the development of the definitive hematopoietic system.
TEL-AML1 fusion in ALL
Abnormalities of the short arm of chromosome 12 (12p), including translocations, inversion, insertions, and deletions, are seen in approximately 10% of childhood ALL cases. 23, 24 Fluorescence in situ hybridization (FISH) studies demonstrated that the majority of these abnormalities affect 12p13 and suggested that a candidate tumor suppressor gene is localized to this region. 25 FISH analyses also showed that some cases described as 12p deletions actually harbored cryptic translocations. [25] [26] [27] In fact, FISH studies of eight ALL cases with partial deletions of 12p indicated that three of the cases harbored the t(12;21), a translocation previously reported only once. 
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Expression of this chimeric gene was driven by the ubiquitous TEL promoter.
Once this translocation was cloned, several groups used molecular genetic approaches to examine its frequency in ALL. 4, 11, [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] Romana et al 30 first demonstrated that TEL-AML1 is the most common genetic alteration in childhood ALL, occurring in 23% of B-precursor cases. Importantly, the t(12;21) was not detected by conventional cytogenetics in any of these cases, underscoring the importance of molecular testing to identify this lesion. TEL-AML1 was not detected in cases T cell ALL, acute myeloid leukemia (AML), or non-Hodgkin's lymphoma. 30 We detected the TEL-AML1 fusion transcript in 22% of randomly selected childhood ALL cases, confirming its high frequency at diagnosis. 4 The fusion transcript has also been detected in adult ALL, albeit at frequencies of only 0-3.4% 11, 30, [40] [41] [42] and only in adults less than 28 years old. 41, 42 It is rarely detected in cases of infant ALL 43 or in ALL patients with Down syndrome. 44 
Mechanism of transformation: TEL-AML1
The structure of TEL-AML1 suggests that it retains the ability to bind to the AML1 DNA target sequence and interact with CBF␤. Moreover, this chimeric protein should retain the normal function of the HLH domain of TEL. Thus, the chimeric TEL-AML1 protein is predicted to alter the normal functions of endogenous AML1 and TEL and to acquire novel functions as a result of the fusion of these different domains into a single molecule (Figure 2 ). Consistent with this hypothesis, TEL-AML1 can directly repress AML1-mediated transcriptional activation. 45 This activity requires both the HLH domain of TEL and the DNA-binding domain of AML1. Repression is not caused simply by competition for binding to the enhancer core motif, but appears to be an active process involving repression mediated through both the HLH domain and a region of AML1 that directly binds to a nuclear co-repressor Proposed mechanism of TEL-AML1 transformation. The TEL-AML1 fusion protein may disrupt the TEL pathway by heterodimerizing with the normal TEL protein (top). By binding to the enhancer core sequence, TGTGGT, TEL-AML1 may also alter the expression of genes normally regulated by AML1-CBF␤.
complex. 45 How the HLH domain contributes to this repression remains undefined. Although this domain directly contributes to TEL-AML1 dimerization and interactions of the chimeric product with wild-type TEL, dimerization does not appear to be mechanistically involved in transcriptional repression. 8, 11, 45 Thus, this domain is likely to contribute to repression through protein-protein interaction with as yet unidentified accessory molecules required for the observed biologic activity.
By dominantly inhibiting the normal function of AML1 in hematopoietic development, TEL-AML1 may directly contribute to hematopoietic cell transformation. This interpretation is supported by studies of other leukemia-associated translocations that alter the function of the AML1/CBF␤ transcription factor complex. A number of these translocations and their fusion proteins have been characterized, including the AMLassociated t(8;21)(q22;q22) (AML1-ETO), 46 ,47 inv(16) (CBF␤-MYH11), 48 and the t(3;21) (AML1-EVI1) [49] [50] [51] seen in myelodysplasia and rare cases of blast transformation of chronic myeloid leukemia (CML). The best studied of these is the AML1-ETO chimeric protein, which directly represses normal AML1-mediated transcription by actively recruiting the nuclear co-repressor complex to the regulatory regions of AML1 target genes. 15, 52 Expression of this protein during development not only results in an inhibition of normal hematopoiesis, but also generates dysplastic multi-lineage hematopoietic progenitors that have an abnormally high self-renewal capacity and readily establish immortal cell lines in culture. 53 Interestingly, these cells are not fully leukemic but appear to have undergone only some of the critical steps required for full leukemic transformation. Clearly, additional mutations that can cooperate with the signal generated through AML1-ETO are required for full transformation. The nature of these cooperating mutations remains to be defined. Similarly, the critical AML1/CBF␤ target genes whose transcription is altered by this dominantly acting fusion protein remain to be identified.
The observation that the HLH domain of TEL can mediate heterodimerization between TEL-AML1 and TEL suggests that the chimeric molecule may also directly alter the normal function of TEL. [8] [9] [10] [11] As previously mentioned, the transcriptional activation of many AML1/CB␤ target genes requires the cooperative activity of Ets family members. TEL-AML1-mediated repression, however, does not involve a direct inhibition of the transcriptional activity of these Ets family members. Nevertheless, TEL-AML1 is likely to directly disrupt normal TEL functions through HLH-mediated heterodimerization. Interestingly, the non-translocated TEL allele is frequently deleted in cases of ALL with the t (12;21) . [54] [55] [56] Loss of heterozygosity (LOH) at the TEL locus is common in childhood ALL, [57] [58] [59] and the four ALL cases from which the TEL-AML1 fusion was first cloned all had deletions of the non-translocated TEL allele. 28 60 However, an analysis of 33 cases of ALL with LOH at TEL revealed no mutations of the other allele, suggesting that TEL is not a classical tumor suppressor. 61 Nevertheless, inactivation of normal TEL function, both through deletion of the non-translocated allele and dimerization of the TEL protein with TEL-AML1, likely contributes to the pathogenesis of TEL-AML1-associated leukemias. It is not yet clear whether loss of TEL leads to transformation by disrupting the TEL pathway or by eliminating TEL-mediated inhibition of TEL-AML1.
It is likely that other secondary events also contribute to the progression of TEL-AML1-associated ALL. Ford et al 62 demonstrated identical TEL-AML1 fusion sequences in the lymphoblasts of identical twins who developed ALL at the ages of 3 years, 6 months and 4 years, 10 months, suggesting that this fusion was generated in utero. The long latency period between the generation of the fusion and the development of leukemia suggests that secondary events are required for the full leukemic phenotype.
Mechanism of transformation: other TEL fusions
TEL was first identified as part of the TEL-platelet derived growth factor receptor ␤ fusion (TEL/PDGFR␤) that is created by the t(5;12)(q33;p13) in chronic myelomonocytic leukemia (CMML) ( Table 1) . 6 Normally, binding of PDGF to wild-type PDGFR␤ leads to dimerization of PDGFR␤, activation of its tyrosine kinase, and autophosphorylation. Subsequent signal transduction pathways affect the mitogenic properties of the receptor. As a result of the t(5;12), however, the HLH domain of TEL is fused in-frame to the PDGFR␤ transmembrane and tyrosine kinase domains. A conserved 65 amino acid region in the HLH of TEL then causes dimerization and constitutive activation of the PDGFR␤ kinase. 8, 9 In addition, the HLH of TEL is essential for conferring IL3-independent growth to Ba/F3 cells. 8 Current research efforts are aimed at determining whether TEL-PDGFR␤ functions through the normal PDGFR␤ signaling pathway or if alternative signal transduction pathways are involved.
The fusion of TEL to a tyrosine kinase also occurs as a result of the t(9;12)(q34;p13), which has been observed in cases of AML, atypical CML, and ALL. 10, 63 This translocation fuses the region encoding the HLH of TEL to the ABL proto-oncogene, which is also involved in the BCR-ABL fusion of CML. 10, 63 As in the case of TEL-PDGFR␤, the HLH of TEL likely serves as a dimerization motif, leading to constitutive ABL tyrosine kinase activity. 10 TEL-ABL is constitutively phosphorylated when expressed in cell lines, confers IL-3-independent growth to Ba/F3 cells, and transforms hematopoietic cells in culture. 10 Similarities between TEL-ABL and BCR-ABL, both in structure and in transforming properties, suggest that the primary, if not only, role of TEL and BCR in transformation is to dimerize ABL. 64 A third example of TEL fused to a tyrosine kinase (Figure 1 ) was cloned from two ALL cases containing the t(9;12)(p24;p13) and one CML case with the t(9;15;12)(p24;q15;p13). 65, 66 In all three cases, chimeric messages encoding TEL-JAK2 fusion proteins were expressed. Like TEL-PDGFR␤ and TEL-ABL, TEL-JAK2 contains the HLH of TEL fused in-frame to the tyrosine kinase domain of JAK2. Recently, Schwaller et al 67 demonstrated that TEL-JAK2 transforms Ba/F3 cells to IL-3 independence and causes a fatal mixed myeloproliferative and T cell lymphoproliferative disease in mice. In addition, the TEL pointed domain and the JAK2 kinase domain were both required for transformation.
In contrast to the three TEL-tyrosine kinase fusions in which the HLH of TEL appears to be essential for transformation, the t(12;22)(p13;q11) fuses the MN1 gene in-frame to the region encoding the DNA binding domain of TEL (Figure 1) . 68 MN1, a nuclear protein of unknown function, has features that suggest it is involved in transcriptional regulation. The MN1-TEL fusion contains almost all of MN1 fused to the Ets domain of TEL, and is driven by the MN1 promoter. This fusion is structurally similar to the EWS-FLIl fusion seen in Ewing's sarcoma and likely transforms cells by altering the expression of TEL target genes.
TEL is also involved in a variety of other translocations in ALL, AML, CML, and myelodysplastic syndrome (MDS) ( Table  1) . While some of the partner genes, such as EVI1 and STL have been identified, others have not yet been isolated. In addition, many of these translocations, like the t(12;21), are accompanied by deletion of the nontranslocated TEL allele. These data suggest that TEL plays a key role both in normal hematopoiesis and in the development of hematologic malignancies. TEL, however, is involved not only in hematologic malignancies; recently, a TEL-NTRK3 fusion was identified in congenital fibrosarcoma cases containing the t(12;15) (p13;q25). 69 TEL-NTRK3 contains the HLH of TEL fused to the protein tyrosine kinase domain of NTRK3, suggesting that HLH-mediated dimerization and constitutive kinase activation play a role in transformation by this fusion, similar to that described for the TEL-PDGFR␤, TEL-ABL, and TEL-JAK2 fusions.
Clinical implications of TEL-AML1
In our initial analysis, we identified 35 TEL-AML1-positive ALL cases; all were 1 to 10 years old with nonhyperdiploid, Bprecursor ALL, suggesting that TEL-AML1 identifies a distinct clinical subgroup of childhood ALL. 4 We have now observed a total of 102 cases of TEL-AML1-positive B-precursor ALL, of whom 91% were 1 to 10 years old and 70% were 2 to 6 years old at diagnosis (Figure 3 ). However, we have also identified one infant and eight teenagers with TEL-AML1-positive ALL (Figure 3 ). Similar age distributions have been reported by the Czech Republic (78% of positive cases were 2 to 4 years old), 70 the Dana Farber Cancer Institute (21 of 22 cases were 2 to 9 years old), 11 and the BFM/AEIOP (all cases were 1 to 12 years old). 32 Although the TEL-AML1 fusion occurs only in B-precursor ALL, 4,11,30-38 50% of cases analyzed at our institution also expressed at least one myeloid-associated antigen, and 48% expressed CD13, CD33, or both. 71 To assess the prognostic importance of TEL-AML1 expression, we analyzed 188 cases of B-precursor ALL, all of which had a minimum follow-up of 3 years. 34 We identified rearrangements of TEL in 48 of the 188 cases (26%), again confirming the high frequency of this lesion. Of the cases with rearranged TEL tested by RT-PCR, all but one expressed the TEL-AML1 fusion transcript. Despite the absence of hyperdiploidy, a favorable prognostic feature, patients with TEL-AML1 had an excellent outcome, with a 5-year event-free survival (EFS) estimate of 91 ± 5%, compared to only 65 ± 5% in those with germline TEL. In a stratified analysis adjusted for age, leukocyte count, risk assignment, and treatment protocol, this difference was highly significant (P = 0.011). To further assess the clinical impact of TEL-AML1, we excluded patients with high-risk translocations [t(4;11), t(9;22), and t(1;19)] and compared outcome among patients with hyperdiploidy, TEL-AML1, or neither feature. Patients with TEL-AML1 had an outcome similar to those with hyperdiploidy (5-year EFS estimates, 91 ± 5% vs 84 ± 6%), and both groups fared significantly better than did the nonhyperdiploid, germline TEL group (stratified P Ͻ 0.001).
Updated outcome results for the TEL-AML1-positive patients indicate a 10-year cumulative incidence of relapse of only 9 ± 5%. All four relapses occurred more than 3 years from diagnosis, and two occurred after complete remissions of more than 7 years. An additional four patients suffered adverse events: one died in remission following a car accident and three developed secondary brain tumors. By contrast, the 140 TEL-AML1-negative cases had a 10-year cumulative incidence of relapse of 34 ± 5%. Because the above analysis included patients treated on two different protocols, we also examined 170 consecutive ALL cases treated on a single protocol. 36 In this study, a stratified Cox proportional hazards model demonstrated that TEL-AML1 was significantly correlated with a favorable prognosis (P = 0.004). Finally, we analyzed the clinical significance of TEL rearrangements among 104 nonhyperdiploid B-lineage patients treated with conventional antimetabolite-based therapy. 33 In this case-control study, the estimated ratio of failure in the germline TEL group to that in the rearranged TEL group was 5.4 (P = 0.0009), again demonstrating a highly significant survival advantage for patients with rearranged TEL.
Several other investigators have also shown a correlation between favorable outcome and TEL-AML1 expression (Table  2) .
11,31,32,37,38 TEL-AML1 was expressed in 32% of childhood B-precursor ALL cases treated at the Dana-Farber Cancer Institute and was significantly associated with better survival.
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With a median follow-up of more than 8 years, none of the 22 TEL-AML1-positive cases has relapsed. Similarly, expression of TEL-AML1 had a significant impact on outcome among ALL patients treated in the German and Italian multicenter therapy trials. 32 In this study, only three of 99 TEL-AML1-positive relapsed (4-year EFS estimate, 90 ± 6%), whereas 27 of the 243 other cases relapsed (4-year EFS estimate, 79 ± 6%). These studies, as well as our own, suggest that the favorable prognosis associated with TEL-AML1 expression is independent of the treatment regimen.
Recent results, however, indicate that treatment intensity does affect the outcome of patients with the TEL-AML1 fusion. 31 An analysis of children with ALL treated on two consecutive clinical trials in Japan demonstrated 5-year diseasefree survival (DFS) rates of 54.5 ± 15% for those with the TEL-AML1 fusion and 61 ± 9.5% for those without the fusion in the first trial. 31 However, with more intensive therapy in the second trial, TEL-AML1-positive patients had a 5-years DFS rate of 100% as compared to 69.9 ± 8.4% for those without the fusion. These data confirm the well-recognized impact of treatment intensity on outcome and suggest that patients with TEL-AML1 may not be candidates for reduction of treatment intensity.
The favorable prognosis of patients with TEL-AML1 has been questioned by two recent studies of patients with relapsed ALL. 73, 74 These studies revealed a 20% to 24% incidence of TEL-AML1 in relapsed cases, similar to that seen at diagnosis. In these studies, patients with TEL-AML1 tended to relapse late, suggesting that large prospective studies with long-term follow-up must be performed before treatment strategies for these patients are altered. Moreover, TEL-AML1-positive patients appeared to have high salvage rates after relapse, although follow-up time was too short to make definitive conclusions. 74 Notwithstanding these findings, three recent studies have each reported less than a 10% incidence of TEL-AML1 in relapsed cases, consistent with a favorable prognosis. [75] [76] [77] Finally, TEL-AML1 has been used as a target to detect minimal residual disease, and may prove to be a useful tool for monitoring this group of patients.
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Conclusions
Although the precise mechanisms of transformation are not completely elucidated, TEL contributes to a variety of human malignancies, both through its deletion and its fusion with other genes. In childhood ALL, TEL-AML1 expression identifies a large group of low-risk patients who have relapse rates of less than 10% on modern treatment protocols. 11, 31, 32, 34, [36] [37] [38] In our studies, 34, 36 the prognostic impact of TEL-AML1 exceeded that of age and leukocyte count, the present standards of risk assessment. We therefore favor treatment protocols based on risk classification schemes that utilize the molecular characterization of leukemic blasts at diagnosis and incorporate the presence of TEL-AML1. 36, 80 Prospective studies of newly diagnosed and relapsed patients now in progress will further clarify the prognostic impact of this fusion.
